Haydale signs a collaboration agreement to be the manufacturing and exclusive nano materials partner to ProMake Limited.
12 July 2021
Haydale, (AIM: HAYD), the global advanced materials group, is pleased to announce that further to a memorandum of understanding signed on 11 November 2020, it has now signed a Collaboration Agreement with ProMake Limited ("ProMake") with respect to the fulfilment of Promake's commitments under the Public Health England ("PHE") National Microbiology Framework.
In line with the UK Government's aim to supply fast turnaround tests in its fight against Covid-19, PHE announced a new National Microbiology Framework in November 2020. There were four discrete lots within this framework and ProMake tendered for Lot 2 and Lot 4.
Lot 2 consisted of the development of goods and services mainly for research and development, experimentation and study. PHE announced on 23 April 2021 that ProMake was one of 69 successful bidders. ProMake is to further develop their prototype BioPod testing device to provide an immediate PCR test result for Covid-19 and other diseases. The multi-use device will utilise graphene and other nano materials within its electronic testing system.
The aim of Lot 4 was to ensure that there is consistent and affordable provision of high quality, safe and compliant testing services which can be delivered efficiently and effectively to support wider clinical services.
PHE announced on the 21 April 2021 that ProMake was one of 50 successful bidders, with their PreVent testing device that allows users to exhale onto a capture unit that is set within a test chamber. The prototype device collects a higher level of viral load, is less invasive than mainstream testing methods and should reduce clinical laboratory testing time and cost.
The collaboration agreement is for Haydale to be the exclusive supplier of the graphene and other nano materials required for the effective functioning of the Lot 2 BioPod device and sets out Haydale's responsibility for the manufacturing supply of several elements of the Lot 4 PreVent testing device.
The Haydale Board considers that it is premature to provide any guidance as to the timing or value to Haydale of this collaboration, but anticipates being able to give a more detailed update over the coming months.
Jason Laing, Co-Founder and CEO at ProMake, said: "We are grateful for the support that Haydale has given us in our successful tender process, and we look forward to working with Haydale to deliver a cost efficient and effective testing service to support the UK Government's fight against Covid-19".
Gavin Leggott, Co-founder and COO at ProMake, said: "We are working with Haydale on a number of projects. We value their technical advice and project management experience, and they are a vital partner in the consortia that we have put together to deliver on these exciting projects".
Keith Broadbent, Haydale CEO, said: "It has been a privilege to work with such innovative thinkers as Jason and Gavin. The opportunity to assist in the fight against Covid-19 is one that we are keen to be involved in".
For further information:
Haydale Graphene Industries plc
Keith Broadbent, CEO
Tel: +44 (0) 1269 842 946
Arden Partners plc (Nominated Adviser & Broker)
Ruari McGirr / Paul Shackleton / Oscair McGrath
Tel: +44 (0) 20 7614 5900
Notes to Editors
Haydale is a global technologies and materials group that facilitates the integration of graphene and other nanomaterials into the next generation of commercial technologies and industrial materials. With expertise in graphene, silicon carbide and other nanomaterials, Haydale is able to deliver improvements in electrical, thermal and mechanical properties, as well as toughness through its state of the art functionalisation. Haydale has granted patents for its technologies in Europe, USA, Australia, Japan and China and operates from five sites in the UK, USA and the Far East.
For more information please visit: www.haydale.com
About Reach announcements
This is a Reach announcement. Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on RNS Reach.